In persons dependent on prescription opioids, tapering with buprenorphine during a 9-month period, whether initially or after a period of substantial improvement, led to nearly universal relapse in the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study, presented here at the American Psychiatric Association 2010 Annual Meeting.
Interested in Monitoring? Call 888-494-2165
Current Customers Call 877-296-6465
Patients & Other Questions Call 877-643-6179
